Advances in the biology and treatment of multiple myeloma

Current Opinion in Oncology

Volumn 11, Issue 1, 1999, Pages 3-8

  Varterasian, Mary L ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRYOSTATIN; CYCLOSPORIN A; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOLOSTATIN 10; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR; HEXAMETHYLENEBISACETAMIDE; INTERLEUKIN 6; MELPHALAN; PAMIDRONIC ACID; QUININE; TOPOTECAN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CLINICAL TRIAL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GROWTH SUBSTANCES; HUMANS; MULTIPLE MYELOMA; T-LYMPHOCYTES; TUMOR STEM CELLS;

EID: 0033032510     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199901000-00002     Document Type: Review

References (79)

1. 1 Hallek M, Bergasagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21. This article is an excellent update of the critical components of the neoplastic transformation in myeloma with a discussion of the therapeutic implications of the proposed model.
2. 2 Barlogie B: Advances in therapy of multiple myeloma. Clin Cancer Res 1997, 3:2605-2613. Presented at a symposium titled "Foundations of Clinical Cancer Research: Perspective for the 21st Century," this is a wonderful review of the development of myeloma treatment written from an historical perspective.
3. 3 Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5-27.
4. 4 National Cancer Institute: 1973-1989 Annual Cancer Statistics Review. Publication number 92-2789. Bethesda: NCI, National Institutes of Health; 1992.
5. 5 Pottern L: Etiology and epidemiology of multiple myeloma and related disorders. In Neoplastic Diseases of the Blood. Edited by Wiernik PH, Canellos GP, et al. New York: Churchill Livingstone; 1985:414-429.
6. 6 Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B: Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement. Br J Haematol 1989, 73:289-295.
7. 7 Pope B, Brown RD, Gibson J, Petersen A, Wiley J, Joshua DE: The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Leuk Lymphoma 1997, 27:83-91.
8. 8 Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thielemans K: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992, 80:2326-2335.
9. 9 Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, et al: Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995, 155:2487-2497.
10. 10 Teoh G, Anderson KC: Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11:27-42.
11. 11 Urashimia M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, et al: The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90:754-765.
12. 12 Johnveaux P, Berger R: Chromosome studies in plasma cell leukemia and multiple myeloma in transformation. Genes Chromosomes Cancer 1992, 4:321-325.
13. 13 Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Keuhl WM: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 1996, 93:13931-13936.
14. 14 Travis P, Kaushal V, Baltz B, et al: Abnormal c-myc transcript size in 70% of patients with multiple myeloma. Blood 1993, 82:1030.
15. 15 Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter TH, Alexanian R, et al: Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 1988, 71:30-35.
16. 16 Neri A, Murphy JP, Cro L, Ferraro D, Tarella C, Baldini L, Dalla-Favera R: Ras oncogene mutation in multiple myeloma. J Exp Med 1989, 170:1715-1725.
17. 17 Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993, 81:128-135.
18. 18 Portier M, Moles JP, Mazars GR, Janteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma. Oncogene 1992, 7:2539-2543.
19. 19 Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 1994, 8:1280-1284.
20. 20 Pettersson M, Jernberg-Wiklund H, Larsson LG, Sunstrom C, Givol I, Tsujimoto Y, Nillson K: Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992, 79:495-502.
21. 21 Brandt SJ, Bodine DB, Dunbar CE, Nienhuis AW: Dysregulated interkleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990, 86:592-599.
22. 22 Zhang XG, Klein B, Bataille R: IL-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74:11-13.
23. 23 Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, et al.: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996, 88:2219-2227.
24. 24 Juge-Morineau N, Harousseau JL, Amiot M, Bataille R: The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk Lymphoma 1997, 24:229-237.
25. 25 Santhanam U, Ray A, Sehgal PB: Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991, 88:7605-7609.
26. 26 Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, et al.: New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997, 90:2437-2444.
27. 27 Bataille R, Barlogie B, Lu Z-Y, Rosi J-F, Lavabre-Bertrand T, Beck T, et al.: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691.
28. 28 Levy Y, Tsapis A, Brouet JC: IL-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 1991, 88:696-699.
29. 29 Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, et al.: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1851-1854. Production of IL-6 by Kaposi's sarcoma herpesvirus-positive bone marrow dendritic cells was found in a majority of the patients studied with myeloma, providing a possible link between myeloma and a virus.
30. 30 Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84:3063-3070.
31. 31 Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al.: Interleukin-6 inhibits fas-induced apoptosis and SAP kinase activation in multiple myeloma cell lines. Blood 1997, 89:227-234.
32. 32 Berenson J, Lichtenstein A: Clonal rearrangement of the beta-T cell receptor gene in multiple myeloma. Leukemia 1989, 3:133-136.
33. 33 Brown RD, Yuen E, Nelson M, Gibson J, Joshua D: The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997, 11:1312-1317.
34. 34 Massaia M, Attisano C, Peola S, Montacchini L, Omede P, Corradini P, et al.: Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993, 82:1787-1797.
35. 35 Borrione P, Montacchini L, Beggiato E, Pileri A, Bianchi A, Massaia M: Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. Leuk Lymphoma 1996, 21:325-330.
36. 36 Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, et al.: Dysregulated fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 1995, 85:3679-3687.
37. 37 Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, et al.: P-glycoprotein expression in human plasma cell myeloma. Blood 1993, 81:490-495.
38. 38 Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Fausssat AM, et al.: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia 1996, 10:1741-1750.
39. 39 Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995, 75:815-820.
40. 40 Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WAS: Mutations in the fas antigen in patients with multiple myeloma. Blood 1997, 90:4266-4270.
41. 41 Landowski TH, Gleason-Guzan MC, Dalton WS: Selection for drug resistance results in resistance to fas-mediated apoptosis. Blood 1997, 89:1854-1861. This group demonstrated that selection for drug resistance in hematopoietic cell lines (including human myeloma 8226) resulted in the simultaneous resistance to fas-mediated apoptosis.
42. 42 Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST: A mechanism of resistance to glucocorticoids in multiple myeloma. Blood 1992, 79:213-222.
43. 43 Krett NL, Zell JL, Halgren RG, Pillay S, Traynor AE, Rosen ST: Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 1997, 3:1782-1787.
44. 44 McElwain TJ, Powles RJ: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983, 2:822-824.
45. 45 Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97.
46. 46 Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al.: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312-1322.
47. 47 Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, et al.: Marrow transplantation for malignant plasma cell disorders. Eur J Haematol 1989, 51(suppl):186-190.
48. 48 Vesole DH, Jagannath S, Glenn LD, et al: Allogeneic BMT in multiple myeloma [abstract]. Proc Am Soc Clin Oncol 1993, 12:A1386.
49. 49 Durie BG, Gale RP, Horowitz MM: Allogeneic and twin transplants for multiple myeloma: an IBMTR analysis. Blood 1994, 84(suppl 1): 792.
50. 50 Reece DE, Shepherd JD, Klingemann H-G, Sutherland HJ, Nantel SH, Barnett MJ, et al.: Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 15:117-123.
51. 51 Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al.: Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995, 85:588-596.
52. 52 Fermand J-P, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, et al.: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993, 82:2005-2009.
53. 53 Harousseau J-L, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al.: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995, 85:3077-3085.
54. 54 Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B: Hemopoietic stem cell transplants for multiple myeloma. Oncology 1994, 8:89-103.
55. 55 Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R: Early myeloablative therapy for multiple myeloma. Blood 1994, 84:4278-4282.
56. 56 Jagannath S, Tricot G, Desikan KR, Naucke S, Mattox S, Dicke K, Barlogie B: 20% 9 year survival after high dose therapy (HDT) ± ABMT for high risk myeloma (MM) ≤ age 50 or b2m ≤ 2.5 mg/L pre-HDT. Blood 1996; 88:509a.
57. 57 Bjorkstrand B, Lkungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al.: Allogenic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European group for blood and marrow transplantation. Blood 1996, 88:4711-4718.
58. 58 Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J: Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 1997, 19:783-789.
59. 59 Varterasian M, Janakiraman N, Karanes C, Abella E, Uberti J, Dragovic J, et al.: Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol 1997, 20:462-466.
60. 60 Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al.: High dose therapy (HDT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with HDT rescue in multiple myeloma (MM): results of a prospective randomized trial [abstract]. Blood 1995, 86:205a.
61. 61 Facon T, Mary JY, Harousseau JL, Attal M, Bosly A, Michaux JL, et al.: Front-line or rescue autologous bone marrow transplantation (ABMT) following a course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM Protocol) [abstract]. Blood 1996, 88:2729a.
62. 62 Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
63. 63 Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Moconduit M, et al.: Single versus double transplant in myeloma: a randomized trial of the "InterGroupe Francais du Myeloma" (IFM) [abstract]. Blood 1997, 90:418a.
64. 64 Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, et al.: Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998, 21:141-145.
65. 65 Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 1996, 87:1196-1198.
66. 66 Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
67. 67 Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. : Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
68. 68 Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211. Thirteen patients with relapsed myeloma after allogeneic BMT were treated with donor leukocyte infusions. Eight of 13 patients responded, 4 with a complete remission. This work expanded on previous anecdotal reports of donor leukocyte infusions.
69. 69 Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, et al.: Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997, 15:667-673.
70. 70 Hsu FJ, Caspar CB, Szerwinski D, Kwak LW, Liles TM, Syrengelas A, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135.
71. 71 Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020.
72. 72 Reichardt V, Okada C, Benide C, Long G, Engleman E, Blume K, Levy R: Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation [abstract]. Blood 1996, 88:481a.
73. 73 Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Lefvert A-K, et al.: Idiotype immunization in combination with GM-CSF of myeloma patients induced a CD8 T-cell response and tumor regression [abstract]. Blood 1996, 88:585a.
74. 74 Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Borsoni R, George S, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602. Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing adverse skeletal events in advanced-stage multiple myeloma patients.
75. 75 Shipman CM, Rogers MJ, Apperty JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997, 98:665-672.
76. 76 Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE: Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1998, 16:589-592. This was the first study showing that the topoisomerase 1 inhibitor, topotecan, had activity (response rate, 16%; CI, 7%-31%) in patients with relapsed myeloma.
77. 77 Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, et al.: 2′,2′-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells 1996, 14:351-362.
78. 78 Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, et al.: Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates bcl-2 expression in human myeloma cells. Proc Natl Acad Sci U S A 1998, 95:162-166.
79. 79 Barille S, Akhoundi C, Collette M, Mellurin M-P, Rapp M-J, Harousseau J-L, et al.: Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997, 90:1649-1655.